PE20040676A1 - Formulacion anticonceptiva que comprende un progestageno y un androgeno disueltos en medio oleoso - Google Patents
Formulacion anticonceptiva que comprende un progestageno y un androgeno disueltos en medio oleosoInfo
- Publication number
- PE20040676A1 PE20040676A1 PE2003000522A PE2003000522A PE20040676A1 PE 20040676 A1 PE20040676 A1 PE 20040676A1 PE 2003000522 A PE2003000522 A PE 2003000522A PE 2003000522 A PE2003000522 A PE 2003000522A PE 20040676 A1 PE20040676 A1 PE 20040676A1
- Authority
- PE
- Peru
- Prior art keywords
- progestagen
- oily medium
- formulation including
- dissolved
- androgen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077126 | 2002-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040676A1 true PE20040676A1 (es) | 2004-09-25 |
Family
ID=29595016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000522A PE20040676A1 (es) | 2002-05-30 | 2003-05-29 | Formulacion anticonceptiva que comprende un progestageno y un androgeno disueltos en medio oleoso |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20060094698A1 (https=) |
| EP (1) | EP1513587A1 (https=) |
| JP (1) | JP2005533036A (https=) |
| KR (1) | KR20050010014A (https=) |
| CN (1) | CN1298330C (https=) |
| AR (1) | AR040131A1 (https=) |
| AU (1) | AU2003238084A1 (https=) |
| BR (1) | BR0311423A (https=) |
| CA (1) | CA2487639A1 (https=) |
| HR (1) | HRP20041126A2 (https=) |
| IL (1) | IL165204A0 (https=) |
| IS (1) | IS7539A (https=) |
| MX (1) | MXPA04011928A (https=) |
| NO (1) | NO20044976L (https=) |
| NZ (1) | NZ536735A (https=) |
| PE (1) | PE20040676A1 (https=) |
| PL (1) | PL373074A1 (https=) |
| RS (1) | RS100904A (https=) |
| RU (1) | RU2328289C2 (https=) |
| TW (1) | TW200404552A (https=) |
| UA (1) | UA80822C2 (https=) |
| WO (1) | WO2003101539A1 (https=) |
| ZA (1) | ZA200409646B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200727920A (en) * | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
| JP6457383B2 (ja) * | 2012-04-06 | 2019-01-23 | アンタレス・ファーマ・インコーポレーテッド | テストステロン組成物の針支援式ジェット注入投与 |
| WO2014093818A2 (en) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men |
| EP4349383A3 (en) * | 2013-02-11 | 2024-06-19 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
| US10369340B2 (en) | 2013-08-12 | 2019-08-06 | Nanomedical Systems, Inc. | Device and method for sustained release of low water solubility therapeutic agent in solubilizer |
| US10792292B2 (en) * | 2019-03-06 | 2020-10-06 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| CN111057120B (zh) * | 2019-12-27 | 2021-04-27 | 苏州翔实医药发展有限公司 | 一种依托孕烯衍生物a及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2970153A (en) * | 1959-07-27 | 1961-01-31 | Leo Ab | Alkoxyphenyl-propionyl esters of 17alpha-hydroxyprogesterone |
| DE3836862A1 (de) * | 1988-10-27 | 1990-05-03 | Schering Ag | Mittel zur transdermalen applikation von steroidhormonen |
| CN1102095A (zh) * | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| CZ187796A3 (en) * | 1993-12-27 | 1997-01-15 | Akzo Nobel Nv | Pharmaceutical preparation |
| US5599302A (en) * | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| AU6614096A (en) * | 1995-07-17 | 1997-02-18 | Schering Aktiengesellschaft | Agent, for transdermal application, containing esters of 3-ketodesogestrel |
| DE69901250T2 (de) * | 1998-06-19 | 2002-10-17 | Akzo Nobel N.V., Arnheim/Arnhem | 7.alpha.-methyl 19-nortestosteron undecanoat mit androgenischer aktivität |
| WO1999067270A1 (en) * | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| ATE474580T1 (de) * | 2000-02-15 | 2010-08-15 | Bayer Schering Pharma Ag | Zusammensetzung zur männlichen kontrazeption, norethisteron enthaltend |
| EP1313511B1 (en) * | 2000-08-23 | 2005-11-30 | Akzo Nobel N.V. | Testosterone ester formulation for human use |
-
2003
- 2003-05-19 TW TW092113496A patent/TW200404552A/zh unknown
- 2003-05-23 EP EP03735716A patent/EP1513587A1/en not_active Withdrawn
- 2003-05-23 CA CA002487639A patent/CA2487639A1/en not_active Abandoned
- 2003-05-23 RS YU100904A patent/RS100904A/sr unknown
- 2003-05-23 AU AU2003238084A patent/AU2003238084A1/en not_active Abandoned
- 2003-05-23 MX MXPA04011928A patent/MXPA04011928A/es not_active Application Discontinuation
- 2003-05-23 JP JP2004508891A patent/JP2005533036A/ja active Pending
- 2003-05-23 PL PL03373074A patent/PL373074A1/xx not_active Application Discontinuation
- 2003-05-23 WO PCT/EP2003/050192 patent/WO2003101539A1/en not_active Ceased
- 2003-05-23 RU RU2004138811/15A patent/RU2328289C2/ru not_active IP Right Cessation
- 2003-05-23 CN CNB038123622A patent/CN1298330C/zh not_active Expired - Fee Related
- 2003-05-23 HR HR20041126A patent/HRP20041126A2/hr not_active Application Discontinuation
- 2003-05-23 NZ NZ536735A patent/NZ536735A/en unknown
- 2003-05-23 UA UA20041109509A patent/UA80822C2/uk unknown
- 2003-05-23 BR BR0311423-6A patent/BR0311423A/pt not_active IP Right Cessation
- 2003-05-23 US US10/515,714 patent/US20060094698A1/en not_active Abandoned
- 2003-05-23 KR KR10-2004-7019341A patent/KR20050010014A/ko not_active Withdrawn
- 2003-05-28 AR ARP030101860A patent/AR040131A1/es unknown
- 2003-05-29 PE PE2003000522A patent/PE20040676A1/es not_active IP Right Cessation
-
2004
- 2004-11-14 IL IL16520404A patent/IL165204A0/xx unknown
- 2004-11-16 NO NO20044976A patent/NO20044976L/no unknown
- 2004-11-18 IS IS7539A patent/IS7539A/is unknown
- 2004-11-29 ZA ZA200409646A patent/ZA200409646B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL165204A0 (en) | 2005-12-18 |
| CA2487639A1 (en) | 2003-12-11 |
| IS7539A (is) | 2004-11-18 |
| CN1298330C (zh) | 2007-02-07 |
| RU2328289C2 (ru) | 2008-07-10 |
| JP2005533036A (ja) | 2005-11-04 |
| NZ536735A (en) | 2007-01-26 |
| MXPA04011928A (es) | 2005-03-31 |
| AU2003238084A1 (en) | 2003-12-19 |
| EP1513587A1 (en) | 2005-03-16 |
| TW200404552A (en) | 2004-04-01 |
| RS100904A (sr) | 2006-10-27 |
| ZA200409646B (en) | 2006-06-28 |
| WO2003101539A1 (en) | 2003-12-11 |
| US20060094698A1 (en) | 2006-05-04 |
| HRP20041126A2 (en) | 2005-04-30 |
| CN1655847A (zh) | 2005-08-17 |
| BR0311423A (pt) | 2005-03-15 |
| PL373074A1 (en) | 2005-08-08 |
| RU2004138811A (ru) | 2005-06-10 |
| AR040131A1 (es) | 2005-03-16 |
| UA80822C2 (en) | 2007-11-12 |
| NO20044976L (no) | 2004-12-23 |
| KR20050010014A (ko) | 2005-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040553A1 (es) | Combinacion que comprende un inhibidor de ibat y tratamiento terapeutico | |
| AR059843A1 (es) | Nuevas composiciones topicas en forma de emulsion ac/ag que comprenden un glicol propenetrante | |
| CR10770A (es) | Mejoras en y relacionadas con mecanismos accionadores adecuados para usarse en dispositivos de descarga de farmacos | |
| GT200300023A (es) | Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo | |
| ECSP034478A (es) | Combinacion terapeutica | |
| DOP2006000050A (es) | Una formulación sólida de dosificación farmaceútica | |
| AR020999A1 (es) | Composiciones y proceso para la elaboracion de isotretinoina | |
| GT200100152A (es) | Nueva composicion farmaceutica para el tratamiento de la obesidad. | |
| AR045203A1 (es) | Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa | |
| NL300343I1 (nl) | 6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1, 4-dieen-17-carbothionzuur-s-fluormethylester alseen ontstekingremmend middel | |
| DE60309895D1 (de) | Estrogenersatztherapie | |
| MX2010002340A (es) | Formulacion en emulsion estable que dificulta la interaccion a traves de la interfase agua-aceite. | |
| CR7611A (es) | Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona | |
| CR7610A (es) | Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona | |
| PE20040068A1 (es) | Decanoato, undecanoato y dodecanoato de etonogestrel | |
| ECSP055888A (es) | Derivados de aril-quinazolin/aril-2-amino-fenil metanona que promueven la liberación de la hormona paratiroides. | |
| PE20040676A1 (es) | Formulacion anticonceptiva que comprende un progestageno y un androgeno disueltos en medio oleoso | |
| GT200600307A (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina | |
| BRPI0415627A (pt) | artigo e método | |
| BR0308660A (pt) | C-17 espirolactonização e 6,7 oxidação de esteróides | |
| ES2196320T3 (es) | Soluciones de polihalofosfacenos estables contra la gelacion. | |
| PA8684501A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
| ITMI20032019A1 (it) | Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono | |
| AR043013A1 (es) | Composicion farmaceutica destinada al tratamiento de la endometriosis | |
| HN1999000063A (es) | Combinaciones terapeuticas que comprenden un moduladir del receptor de estrogenos selectivo y hormona paratiroidea. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| MH | Renunciation |